Hafez, N., Soliman, H. H., Fu, S., Gelmon, K. A., Razak, A. R. A., Munster, P. N., … Kim, J. W. (2020). Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Hafez, Navid, Hatem Hussein Soliman, Siqing Fu, Karen A. Gelmon, Albiruni Ryan Abdul Razak, Pamela N. Munster, Ulka N. Vaishampayan, et al. “Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Hafez N, Soliman HH, Fu S, Gelmon KA, Razak ARA, Munster PN, et al. Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Hafez, Navid, et al. “Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Hafez N, Soliman HH, Fu S, Gelmon KA, Razak ARA, Munster PN, Vaishampayan UN, Kato S, Lara P, Swisher EM, Nixon AB, Patel A, Shyr Y, Ivy SP, LoRusso P, Kim JW. Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. 2020.